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Early detection of nephrotoxic effects in thalassemic patients receiving
desferrioxamine therapy. Nineteen transfusion-dependent -thalassemia
major patients were included in the study. Six of these patients underwent
chelation therapy with desferrioxamine by subcutaneous infusion (50
mg/kg/12 hr) and 13 received intravenous infusion (50 mg/kg/6 hr or 100
mg/kg/24 hr). BUN, creatinine, creatinine clearance, 132-microglobulin,
urinaiy 132-microglobulin and urinaiy growth hormone excretion were
evaluated during desferrioxamine treatment. Thirteen out of nineteen
patients presented tubular damage indicated by increased excretion of
urinary 32-microg1obulin. 85% (11 of 13) of these patients showed more
serious tubular damage, as demonstrated by concurrent increased urinary
growth hormone excretion. Moreover, a positive correlation between
urinary growth hormone excretion and urinary /32-microglobulin was
observed (P < 0.05).
Increased proteinuria is one of the most common methods for
renal function evaluation.
Numerous studies have reported renal failure after desferriox-
amine (DFX) therapy in patients with homozygous beta thalasse-
mia major (TM) [1, 2].
This study evaluates early indicators of renal damage in thalas-
semic patients undergoing iron chelation therapy. Urinary excre-
tion of 2-microglobulin (!32m) and growth hormone (GH) were
measured as markers of impaired renal function [3].
Methods
Nineteen TM patients (8 males and 11 females) were studied.
None had known diabetes or impaired glucose tolerance. All
patients had received transfusional and chelation DFX therapy
and were divided into three groups according to the therapy
protocol.
The first group (N = 6, median age 29 years, range 5 to 32)
received DFX 50 mg/kg body wt/12 hr by subcutaneous infusions,
for a minimum of four years to a maximum of 20 years; the second
group (N = 6, median age 27.5 years, range 21 to 29) was treated
with the same dosage of DFX by intravenous infusions over six
hours; the third group (N = 7, median age 20 years, range 17 to
28) received DFX 100 mg/kg body wt/24 hr by Port-A-Cath.
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All patients were treated six days a week (Table 1).
BUN, creatinine and creatinine clearance (Car)were analyzed
on early morning samples for renal function evaluation. j32-
microglobulin and urinary 2-microglobulin (u-132m) were de-
tected by immunoenzymatic assay (IMX J32m, MEIA-Abbott,
Texas, USA) upon entry into the study, and after four weeks in the
second group and after five months in the third group.
Urinary /32m can be degraded in the bladder at pH levels below
5.5. This risk is decreased by the administration of an oral dose of
sodium bicarbonate at least eight hours before urine collection.
The mean pH value of urinary samples was 6.87 0.66.
Urinary GH (u-GH) was measured using both an immunora-
diometric assay (IRMA; Biomerieux, Marcy-L'Etoile, France)
and an immunoenzymatic assay (ELISA; NovoNordisk, Bagvaerd,
Denmark) [4, 5] from the early morning urine samples on three
consecutive days. The collection period and the urine volume
were recorded. Urinary growth hormone and u-132m were ex-
pressed as total amount excreted during the collection period by
multiplying urinary concentration (ng/liter and xg/liter) by the
respective urine volume. Excretion was expressed amount per
eight hours. We also evaluated u-GH and u-32m in a control
group of 30 normal subjects, aged 5 to 37 years. The normal range
for u-GH by IRMA was ito 9.5 ng/liter/8 hr and by ELISA, 0.7 to
9.9 ng/liter/8 hr. Normal values for u-/32m were 2 to 130 jkg/liter/8
hr (Table 2).
The first group of patients was tested once; the second group
was followed up once a week for four weeks. The third group was
evaluated once a week for five months. Statistical analysis was
Table 1. Clinical characteristics of thalassemic patients
Patients (N) 6 6 7
Median age 29 27.5 20
years
Range years 5—32 21—29 17—28
Sex 4f—2m 3f—3m 4f—3m
DFX dose 50 mg/kg s.c. 50 mg/kg i.v. 100 mg/kg i.v.
Time infusion hr 12 6 24
Ferritin ,.Lg/litera 1295 602.3 6126 3567 6011 3323
Abbreviations are: s.c., subcutaneous; i.v., intravenous; DFX, desferri-
oxamine.
Data are mean SD
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Table 2. Renal assessment in thalassemic patients
Patients
Scr
6—150 mol/liter
Ccr
mi/mm
u-132m
2—130 pg/liter/S hr
Baseline value
u-GH
(1—9.5 nglliter/8 hr)
IRMA
(0.7—9.9 ng/liter/8 hr)
ELISA
1 66 103.2 14 3.45 2.74
2 79 84.6 33 2.05 1.3
3 91 80.2 23.6 2.90 1.53
4 79 80.6 68.6 1.56 1.4
5 72 48.7 156.8 24.99 23.86
6 101 78.8 17.4 12.67 11.05
Mean SD 81.33 12.0 79.35 17.54 52.23 54.89 7.94 9.32 6.98 9.08
Range 66—101 48.7—103.2 14—156.8 1.56—24.99 1.3—23.86
Baseline value After 4 weeks
7 95 85.5 43.8 412 5.14 6.99
8 91 102.2 254 32 2.68 6.09
9 101 65.2 63.8 2588 211.28 87.79
10 129 74.1 26.9 3832 15.60 10.168
11 102 79.1 30 6100 23.05 13.72
12 86 66.9 67.2 144 4.18 3.88
Mean SD 100.6 15.1 78,7 13.7 80.95 86.40 2184.6 2455.4 43.65 82.50 21.44 32.69
Range 86—129 66.9—102.2 26.9—254 32—6100 2.68—21 1.28 3.88—87.79
Baseline value After 5 months
13 110 78.9 23.7 2606 99.08 44.77
14 69 47.2 36 3200 63.51 42.34
15 104 75.1 38 3470 70.05 50.31
16 93 31.2 21 8969 156.24 73.88
17 103 74.4 33 5200 70.24 53.03
18 83 85.4 19 162 2.79 2.67
19 88 66.3 28 135 39.56 23.07
Mean SD 92.86 14.2 65.5 19.4 28.39 7.39 3391 3057 71.64 47.87 41.44 22.80
Range 69—110 31.2—85.4 19—38 135—8969 2.79—156.24 2.67—73.88
Fig. 1. Urinaiy /32-microglobulin levels in
thalassemic patients undergoing intravenous
DFX therapy.' (A) baseline (U) and after 4
weeks (E) DFX50 mg/kgI6 hr; (B) baseline
(U) and after 5 months (D) DFX 100 mg/kg/24
hr. The mean values of u-f32m were
significantly increased in all groups (P <
0.05). The values are expressed in log scale.
performed for paired samples. Correlation between u-132m and
u-GH was determined by linear regression analysis.
Results
The mean f32m values were in the normal range for all patients.
In the second and third groups examined, the mean values of
u-/32m were significantly increased (P < 0.05; Fig. 1). No signifi-
cant correlation was found between mean values of serum creat-
mine and CCr. In one of six patients who received DFX by
subcutaneous infusions, u-132m values were higher than normal; in
five of six patients of the second group, u-2m values increased 47
times normal values after four weeks of treatment, After the fifth
month of treatment, all patients of the third group showed an
increased u-J32m value 69 times higher than the normal range.
Eighty-five percent (11 of 13) of the patients with high u-g32m
values showed increased u-OH levels. A correlation was found
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reversible, may be related to the dosage of DFX, the degree of
hydration and the duration of treatment.
Our results suggest that DFX related nephrotoxicity may be
associated with the impaired tubular function as demonstrated by
the significant increase of u-/32m and u-GH in the intravenous
treated groups of patients (Figs. 1 and 3). The progressive
increase of these markers suggest that the occurrence and the
extent of tubular damage due to DFX may depend on the
duration of treatment, dosage and in particular mode of admin-
0 50 100 150 200 250 istration.
In thalassemic patients an abnormal pulsatile GH secretion has
been reported [5]. However, according to previous reports u-GH
levels may be elevated despite a normal serum GH level in the
presence of renal failure, especially in patients with tubular
dysfunction [121.
In two patients (7 and 12) u-GH levels were normal in presence
of high u-2m levels; one patient (no. 6) who discontinued
intensive iron chelation therapy (100/kg/i.v.!day) one year ago
showed a high level of u-GH and normal level of u-f32m.
Considering the different sizes between the GH and ,m
molecules, the high excretion of u-GH indicates a more serious
and insidious tubular damage which repairs more slowly.
Moreover, it is possible that in the tubular epithelium the side
and mechanism of absorption and degradation of u-GH and
Discussion
u-/32m are slightly different [13].
132-microglobulin (/32m) is a low molecular weight protein (11.8 A positive correlation was found between u-GH and u-p2m
kD), first isolated from urine of patients with Wilson's disease [61; values, although the degree of correlation differed depending on
95% of f32m is eliminated via glomerular filtration [7]. Urinary the u-GH assay used (Fig. 2 A and B). In thalassemic patients
132m has been shown to be a sensitive index of proximal renal undergoing traditional or intensive iron chelation therapy it is
tubular function [7, 8]. necessary to monitor tubular damage, which is often subclinical.
Renal handling of GH (22 kD) has been investigated in rats [9]. Urinary /32m levels represent a simple assessment of this damage.
Results show that GH is extensively filtered and subsequently Tubular damage does not negate the efficiency or the utility of
reabsorbed in the proximal tubules [10]. DFX treatment.
This study confirms previous studies reporting renal function Indeed, the survival and quality of life for thalassemie patients
damage in patients undergoing DFX intravenous chelation ther- with iron overload have been increased by this treatment. Reduc-
apy infusion [1, 2]. Two mechanisms have been suggested for tion of the DFX dosages should be considered if elevated u-f32m
desferrioxamine induced nephrotoxicity: (1) an acute decrease in levels are observed, and it is advisable to stop treatment if
renal perfusion in the presence of unchanged systemic blood augmented /32m excretion is present in association with a progres-
pressure due to inhibition of prostaglandin synthesis [11], and (2) sive Cr reduction.
inhibition of tubular reabsorption of salts. This damage, usually High u-GH levels in addition to these variables confirm more
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Fig. 3. Urinary growth hormone levels in all patients measured by IRVL4 (•)
and ELISA (LII) assays.
u-GH, ng/Iiter/8 hr
Fig. 2. Correlation between u-GH and u-f32m by ELISA assay (A, r = 0.66,
P <0.05) and by IRMA assay (B; r = 0.60, P <0.05).
between u-f32m and u-GH, although the degree of correlation
varied according to the different u-GH assay used (ELISA r
0.66 P < 0.05; IRMA r = 0.60, P < 0.05; Fig. 2A and B). Urinary
growth hormone values were statistically significant for all three
groups (P < 0.05, ELISA) (Fig. 3). Renal assessment for all
patients is shown in Table 2.
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serious tubular damage. Moreover, the measurement of u-GM
cannot be used to evaluate hypothalamo-pituitary function in
patients with subclinical renal failure, except after evaluation of
u-f32m, especially in thalassemic patients undergoing DFX ther-
apy.
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